Exclusive Summary

• Backed by world-class US-FDA and PIC/S GMP certifications, securing fast-track registration and bypassing lengthy site inspections in highly regulated global markets.
• Targets a massive, recession-proof market of approximately 1.2 billion menopausal women globally by 2030, guaranteeing high-frequency and stable procurement demands.
• As a mature off-patent blockbuster, it carries zero IP risks and leverages Chinese manufacturing economies of scale to offer overseas distributors significantly higher profit margins than the originator.
• Represents the undisputed first-line Standard of Care (SoC) for Hormone Replacement Therapy (HRT) universally recommended by major clinical guidelines, requiring zero market education efforts from distributors.